Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Edison issues report on BB Biotech (BION)

eqs_en 
1 0 26.06.24
Edison issues report on BB Biotech (BION)
 

Edison Investment Research Limited
Edison issues report on BB Biotech (BION)

26-Jun-2024 / 13:08 GMT/BST
The issuer is solely responsible for the content of this announcement.

 

London, UK, 26 Juni 2024

 

Edison issues report on BB Biotech (BION)

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

[email protected]

+44 (0)20 3077 5700

Connect with Edison on:

 

LinkedIn www.linkedin.com/company/edison-group-/

X  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1933835  26-Jun-2024 

fncls.ssp?fn=show_t_gif&application_id=1933835&application_name=news&site_id=sharewise~~~202ee175-2c72-4a50-a0f7-89cd8fcfa533

BB Biotech AG Stock

€59.60
-0.170%
BB Biotech AG shows a slight decrease today, losing €0.000 (-0.170%) compared to yesterday.

Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Alnylam reported that the benefits of treatment were consistent across major sub-groups of trial participants, with adverse events and geometry dash side-effects leading to study discontinuation similar for those given the drug and those given a placebo.
Show more

performerdiscus 
0
Report Share
02.07.24
Show more
Not a member yet? Sign up for free!